Stockreport

BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion [Yahoo! Finance]

BioAge Labs, Inc.  (BIOA) 
Last bioage labs, inc. earnings: 8/3 07:00 am Check Earnings Report
US:NYSE Investor Relations: investor.bio-amber.com
PDF in Phase 1 with 24-hour IC90 coverage at 60 mg, ~93% IL-1ß suppression, and pronounced biomarker changes including ~86% reduction in hs-CRP and ~50% reduction in IL-6 in [Read more]